PRRT (peptide receptor radionuclide therapy)
A radioactive drug for neuroendocrine tumours: a small peptide that homes to the somatostatin receptor on the tumour cells carries lutetium-177, which irradiates them from within. Given four times, two months apart.
Overview
Neuroendocrine tumours overexpress somatostatin receptor 2, imaged with gallium-68 or copper-64 DOTATATE PET and treated first with cold somatostatin analogues (octreotide, lanreotide) for symptom and growth control. 177Lu-DOTATATE (NETTER-1, approved 2018) improved progression-free survival dramatically in midgut NETs and NETTER-2 (2024) moved it to first line in high-grade tumours; 177Lu-edotreotide (COMPETE) followed. Alpha-emitting versions (212Pb-DOTAMTATE, 225Ac-DOTATATE) are in phase 3 for PRRT-refractory disease. Toxicities are marrow suppression, kidney dose and a small risk of MDS. Together with radioiodine and PSMA therapy it defines the theranostic model.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · Somatostatin receptor 2 is a hormone receptor densely present on neuroendocrine tumours, and was the first theranostic target to reach routine care.
Showing the target this term concerns: Somatostatin receptor 2.
Similar pages
not linked directly; found by shared links- CompanyMolecular Targeting Technologies
Shares Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT).
- Key paperNETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours
Shares Grade 3 well-differentiated neuroendocrine tumour, Dosimetry, Theranostics, Pancreatic neuroendocrine tumours.
- AgentLutetium-177 dotatate (radioligand equivalent)
Shares Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT).
- RoadmapSSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha
Shares Lead-212, Gallium-68 DOTATATE (and Cu-64 DOTATATE), Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours.
- Pairing68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE), Copper-64, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT).
- PairingSSTR PET → PRRT
Shares Copper-64, Theranostics, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT).
- TrialCOMPETE
Shares Grade 3 well-differentiated neuroendocrine tumour, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Somatostatin receptor 2.
- PairingBeta PRRT → alpha PRRT
Shares Alpha vs beta emitters, Lead-212, Lutetium-177 dotatate, Targeted alpha therapy.